Change of Advisers

    RNS Number : 4528V
  Phynova Group PLC
  29 May 2008
   


    [29] May 2008




    Phynova Group PLC

    ("Phynova" or the "Company")


    PHYNOVA APPOINTS JOHN EAST & PARTNERS AND CAPITAL MS&L


    Phynova (AIM: PYN), the developer of prescription pharmaceuticals derived from plants used in Chinese medicines, announces the
appointment of John East & Partners Limited (*JEP*) as nominated adviser and Capital MS&L (*Capital*) as investor relations, corporate and
financial PR agency. Both appointments start with immediate effect.

    Phynova combines its expertise in drug development and knowledge of plant based medicines to develop drugs which target unmet
therapeutic needs including infectious disease, metabolic disease and cancer. The appointment of JEP and Capital follows the Company's
listing of its American Depository Receipts  on the US International OTCQX in New York. It was one of the first AIM listed companies to list
on OTCQX and retains its UK listing.

    Robert Miller, Chief Executive Officer of Phynova said: 

    "Phynova has reached a critical stage in its growth strategy and these two appointments signify a positive step forward for the Company.
We selected both companies on the basis of their insight, advice and sector expertise and look forward to working closely with them as our
company develops and expands."

    The JEP team will be led by John East and Simon Clements. Capital's team will be led by Mary Clark and Penny Freer.



    -ENDS-













    For further information, please contact: 

 Phynova Group PLC              Tel: [phone]
 Tony Mills
  
 John East & Partners Limited  Tel: [phone]
 John East/Simon Clements
  
 Capital MS&L                  Tel: [phone]
 Mary Clark/Penny Freer
  


     :  

    Notes to editors:


    About Phynova

    Phynova is a UK incorporated company developing prescription pharmaceuticals derived from plants used in Chinese medicines. The Company
is focused on viral and bacterial diseases, metabolic diseases and cancer. Phynova´s lead product for hepatitis C has now completed a Phase
I/II trial in the US and the Phase IIb trial is scheduled to commence in the first half of 2008. Two further products, for fatty liver
disease and post-operative ileus, are targeted for entry to the clinic over the next six months and there are a further four products in
preclinical development. 

For further information please visit www.phynova.com.

    About John East & Partners

    JEP is a member firm of the London Stock Exchange, specialising in providing corporate finance advice and raising capital for smaller
public companies and companies seeking a public listing. It acts as nominated adviser and broker to 38 companies whose shares are quoted on
AIM and as corporate adviser to PLUS market companies. Its broad scope of work covers IPO advice and fundraising, secondary fundraisings,
public company mergers and acquisitions, takeover transactions and the provision of general financial advice. 

    For further information please visit www.johneastpartners.com.

    About Capital MS&L

    Capital MS&L is an international financial communications consultancy, with offices based in London, Manchester, New York and Dubai. The
firm offers corporate and financial public relations, investor relations and capital markets transaction support to a range of ambitious,
international clients. 

    The company is part owned by global public relations firm MS&L, which is in turn owned by Publicis Groupe, the world's fourth largest
marketing services group. 

    For further information please visit www.capitalmsl.com. 
This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
APPQVLFLVEBBBBE